Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model
AC102 regenerates connections between the inner ear and auditory nerve in a preclinical model and eliminates tinnitus. Efficacy of AC102 on sudden hearing loss and tinnitus currently investigated in clinical trial.
Share
In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, they nearly disappeared in the AC102 group after five weeks – in clear contrast to the placebo group. Additionally, the AC102 group showed significantly less loss of synaptic connections between the inner ear and the auditory nerve than the placebo group. This damage is considered to be a potential cause of tinnitus: 'Our results suggest regeneration of inner ear structures that are critical for tinnitus and could be an important milestone and a glimmer of hope for a causal treatment of tinnitus,' says the study's first author, Dr. Konstantin Tziridis from Erlangen University Hospital.
About two-thirds of sudden hearing loss patients also suffer from tinnitus, which persists in around 30% of cases. Although 10-15% of adults experience tinnitus, no effective causal treatment exists. AC102 has the potential to become a new treatment option. In a preclinical acoustic trauma model, it almost completely reversed sudden hearing loss. Since tinnitus often accompanies sudden hearing loss, AudioCure is investigating AC102's potential efficacy also against tinnitus in its ongoing study. AudioCure's CEO, Dr. Reimar Schlingensiepen, emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients and doctors who have no approved drug treatment available at present." AC102 has already been tested for safety and tolerability in a clinical study and is currently being examined in a Europe-wide Phase-2-study in patients for its effectiveness in sudden hearing loss and tinnitus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
31 minutes ago
- Medscape
Brain Changes Linked to Dementia Found in Ex-Rugby Players
Two studies led by researchers at Imperial College London (ICL) have identified structural brain changes and blood biomarkers linked to dementia in former professional rugby players. The findings provide the first prospective evidence of physical brain and blood abnormalities in this group. Previous research had already shown that elite rugby players face a higher risk of neurodegenerative diseases later in life. The studies examined links between repeated head impacts in rugby and conditions such as Alzheimer's disease and chronic traumatic encephalopathy (CTE). Post-mortem examinations of former players have shown neuropathologies consistent with repetitive brain trauma. Traumatic brain injury, already a known risk factor for neurodegeneration, contributes to an estimated 3%-15% of dementia cases in the general population. While recent advances in fluid and imaging biomarkers have transformed dementia diagnosis, these techniques have not been systematically applied to rugby players previously exposed to multiple head impacts. Study Cohort and Methods The research involved 200 ex-professional rugby players aged 30-61 (median age, 44), all of whom had self-referred with brain health concerns but had no dementia diagnosis at baseline. At least one previous concussion while playing was reported by 193 (96.5%) of the former players, with a median of seven concussions. The rugby group was compared with 33 age- and sex-matched healthy controls with no evidence of previous head trauma or dementia onset. Participants were 90% male. The median rugby career lasted 10.5 years, with 63% playing as forwards and 37% as backs. Mental Health and Behavioural Symptoms The former players scored higher on self-rated scales of depression, anxiety, and post-concussion symptoms than those in the control group, though not on sleep quality. These symptoms, along with behaviour ratings of executive dysfunction and neuropsychiatric symptom severity, were more prevalent among individuals who had experienced a greater number of self-reported concussions. However, this was unrelated to the number of years played, or position of play. Despite frequent subjective memory complaints, the performance of players in cognitive testing did not differ significantly from that of the control group. However, 24 former players, particularly those who had played as forwards and those who had reported more concussions, met the research criteria for CTE syndrome based on neurobehavioural disturbance. This was determined with low provisional levels of certainty: 21 were classed as 'suggestive.' three as 'possible.' and none as 'probable/definite.' Seven of the 24 had cognitive impairment, 12 had neurobehavioral dysregulation, and five had both. Imaging Findings 3T MRI imaging showed the presence of cavum septum pellucidum in 24% of players, compared with 12% of controls. This was more common in those who had experienced more concussions. They also showed reduced volumes in the frontal and cingulate cortices, with reduced white matter and lower hippocampal volume associated with longer career durations. Only 4.6% showed trauma-associated white matter changes on diffusion tensor imaging. Elevated Blood Biomarkers Using ultrasensitive digital enzyme-linked immunosorbent assays, researchers analysed fluid biomarkers associated with neurodegeneration. Key findings included: Phospho-tau217 levels were 17.6% higher in former players 23.1% had elevated phospho-tau217 9.0% had raised plasma neurofilament light While levels were lower than in late-onset Alzheimer's patients, players with elevated markers had more severe neuropsychiatric symptoms, including depression and anxiety. Frontal brain volumes correlated negatively with neurofilament light, and hippocampal volumes correlated negatively with phospho-tau217. The findings were published simultaneously in two papers in the journal Brain . Professor David Sharp, director of the UK Dementia Research Institute Centre for Care Research & Technology at ICL, who co-led the work, said: 'We didn't see any cases of early dementia in this group of former players, which is reassuring. However, the changes in blood biomarkers and brain imaging abnormalities show some long-term effects of repeated head impacts on the brain.' The studies are set to continue for a further 4 years. Calls for Action on Player Safety 'Nearly half of dementia cases are linked to known health and lifestyle risk factors, including traumatic brain injury from contact sports like rugby,' said Dr Jacqui Hanley, head of research at Alzheimer's Research UK. While not much is known about how such injuries cause changes to the brain, 'deepening our understanding could ultimately help lower dementia risk for professional sportspeople.' Hanley called for stronger efforts to reduce head injury in contact sports, stating: 'Reducing traumatic brain injury in contact sports is critical to help prevent brain damage and minimise dementia risk for the players.' The Alzheimer's Society echoed the concern, noting that professional rugby players face approximately twice the risk of dementia. They called for accurate data on injury patterns and their long-term effects. However, they also stressed that physical activity remains one of the most effective ways to reduce dementia risk. The Dementia Trust has warned that repeated tackles, scrums, and collisions can contribute to CTE among rugby players and noted a rise in early-onset dementia among retired professional players. In 2023, a group of 260 former professionals launched a lawsuit against World Rugby, the Welsh Rugby Union, and the Rugby Football Union. They alleged negligence in failing to protect players from the risk of neurodegenerative diseases.
Yahoo
37 minutes ago
- Yahoo
Surmodics still recovering after June cyberattack
Surmodics has revealed that it is still recovering after it was hit by a cyberattack in June 2025. In a Form 8-K filed with the US Securities and Exchange Commission (SEC), the maker of the Pounce XL thrombectomy system for clot removal said that on 5 June, the US-based company discovered that a third party had gained unauthorised access to 'certain' IT systems, rendering them 'unavailable' to the company. Surmodics has been able to continue accepting customer orders and shipping products without any customer impact by using alternative IT systems following the breach. The company noted that to its knowledge, the threat actor had not released any of its data, including any third-party data, or used any such data for any fraudulent purposes. It continues to evaluate the 'scope and details of the IT data' stolen in the attack. Containment measures were initiated once the breach was identified, with certain IT systems taken offline. Surmodics added that it implemented its security incident response plan and that remaining IT systems and data are currently being restored and validated. Surmodics is not the only medtech company to have experienced a cyberattack this year. In May, medical technology company Masimo revealed that 'unauthorised activity' had been detected on its on-premise network in April. The incident disrupted certain activities at the patient monitoring company's manufacturing facilities and hindered its ability to process and ship customer orders effectively. According to Masimo, the attack did not affect its cloud-based hospital data systems, with no evidence of any employee or patient data being compromised. Research indicates that cyberattacks on healthcare organisations are on the rise, due in part to outdated legacy systems and increased vulnerabilities due to the rise of Internet of Things (IoT) devices and the overall richness of the data available to bad actors. According to KPMG, due to cyber threats, the functioning of healthcare systems has reached a 'tipping point'. With the rise of AI-powered medical transcription tools being deployed in healthcare systems, KPMG states that there is an increasing onus on chief information security officers (CISOs) to ensure that data privacy, access management, and other security protocols are well-developed as a means to protect sensitive patient information. According to GlobalData, cybersecurity spending by healthcare providers is growing at a CAGR of 12.5% to reach a valuation of $10.9bn by 2027. "Surmodics still recovering after June cyberattack" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
44 minutes ago
- Business Wire
Japan Delegation Concludes Visit to North Carolina to Explore Life Sciences Partnerships
ATLANTA--(BUSINESS WIRE)--A high-level Japanese delegation specializing in life sciences concluded a three-day visit to North Carolina (June 24–26), further strengthening ties between Japanese and U.S. leaders in the sector. Organized by the Japan External Trade Organization (JETRO) and co-organized by the Economic Development Partnership of North Carolina (EDPNC), the Research Triangle Regional Partnership, Greater Winston-Salem, Inc., and the Charlotte Regional Business Alliance, the visit included tours of key facilities within North Carolina's thriving life sciences ecosystem. The delegation commenced its visit with a meeting with Governor Josh Stein, followed by a tour of the North Carolina Plant Sciences Building at North Carolina State University and the Biomanufacturing Training and Education Center (BTEC), where they explored academic–industry collaboration in workforce development. The group also visited Spark LS, a 109-acre advanced life science campus, FUJIFILM Diosynth Biotechnologies, and Astellas Gene Therapies. On the second day, the delegation visited the Innovation Quarter in Winston-Salem and toured the Wake Forest Institute for Regenerative Medicine (WFIRM) to gain insights into cutting-edge initiatives in regenerative medicine. Additional site visits included Winston Starts, Ricoh, Mercodia, and Charter Medical. The day concluded with a warm welcome from Mayor Allen Joines. On the final day, the delegation visited the North Carolina Research Campus in Kannapolis and toured the North Carolina Food Innovation Lab. They also visited Coddle Creek Capital and the University of North Carolina Nutrition Research Institute. The visit concluded at The Pearl, Charlotte's emerging hub for healthcare innovation and scientific advancement. JETRO looks forward to deepening its collaboration with the State of North Carolina, building on the growing momentum between Japan and the region in advanced technology sectors.
